Vanda Pharmaceuticals to Present at the Bank of America 2008 Healthcare ... ( Presentation Will be Webcast Live...)

Vanda Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference

Date:5/8/2008

Presentation Will be Webcast Live and Archived on Company's Website

ROCKVILLE, Md., May 8 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA), a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders, today announced that the company will deliver a corporate presentation on Tuesday, May 13, 2008, at 5:20 p.m. Pacific Time.

The presentation will take place as part of the 2008 Bank of America Healthcare Conference at the Four Seasons, Las Vegas, Nevada. The presentation will be available live on the Vanda Website, where it also will be archived for 30 days.

To access the presentation, log on to http://www.vandapharma.com and click on the Presentations option in the Investor Relations section. Please connect to the website several minutes prior to the start of the live presentation

About Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. The company has three product candidates. Vanda's lead product candidate, Fanapta(TM) (iloperidone), for which Vanda has recently submitted an NDA to the FDA, is a compound for the treatment of schizophrenia. Vanda's second product candidate, tasimelteon (VEC-162), is a compound for the treatment of sleep and mood disorde
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2
Related biology technology :

1. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
2. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
3. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
6. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
7. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
8. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
9. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
10. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
11. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)

Post Your Comments:

(Date:12/15/2009)... Reportlinker.com announces that a new market research ... The Future of Orphan Diseases ... Analysis and Reimbursement ,, ... Summary ,, The author has released ... Diseases Therapeutics - Market Forecasts to 2015, ...

(Date:12/15/2009)... Minn., Dec. 15 The Mosaic Company (NYSE: ... fiscal year 2010 earnings results and financial tables on ... on the New York Stock Exchange. Results will ... ,, The Company will host a conference call with ... the results. The call will begin at 11:00 ...

(Date:12/15/2009)... PHILADELPHIA and LONDON, Dec. 15 ... Thomson Pharma ® has become the first ... trial protocol and outcome information. This highly anticipated ... Pharma customers this month. ,, ... trial intelligence from registries, publications, press releases, conferences, ...

(Date:12/14/2009)... -- Vermillion, Inc. (Pink Sheets: VRML), a ... Wallen, Ph.D. Chief Scientific Officer, Senior Vice ... will be joining its board of directors ... ,, "Bill brings more than 20 years ... biotechnology," said Gail Page, Vermillion Executive Chairperson. ...

[0] Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement [0] Mosaic Announces Second Quarter Fiscal Year 2010 Earnings Release and Conference Call [0] Thomson Reuters is First to Offer Fully Integrated Pipeline and Clinical Trials [0] Vermillion Announces Appointment of William C. Wallen, Ph.D. to Board of Directors

... Following the,completion of the Phase II clinical development of ... end of Phase,II meeting with the FDA to discuss ... there was an open and highly constructive discussion with ... the first ever formal discussions with the,agency to license ...

... Holmes Named PartnerLONDON, March 3 Index Ventures ... stage fund, Index Ventures V. The fund is dedicated ... and clean technology sectors across Europe, the United States and ... has raised in the past ten years and reinforces the ...

... Stock Exchange Symbol: MSEDMONTON, March 2 /PRNewswire-FirstCall/ - BioMS ... treatment of multiple sclerosis (MS), announced that effective on ... purchase warrants, each of which entitles the holder to ... of $5.00 per share, will be extended from March ...

Other Biology Technology:Bavarian Nordic Has Essentially Agreed a Pathway for the Licensure of IMVAMUNE(R) With the FDA After Successful End of Phase II Meeting 2 Bavarian Nordic Has Essentially Agreed a Pathway for the Licensure of IMVAMUNE(R) With the FDA After Successful End of Phase II Meeting 3 Index Ventures Closes Euro 350 Million Early Stage Fund 2 BioMS Medical warrant extension 2

Bavarian Nordic Has Essentially Agreed a Pathway for the Licensure of IMVAMUNE(R) With the FDA After Successful End of Phase II Meeting Index Ventures Closes Euro 350 Million Early Stage Fund BioMS Medical warrant extension

(Date:12/15/2009)... Fla. When treating devastating brain diseases such as ... bags to find something to help a patient. , ... help the vast majority of patients with ataxia ... coordination. , University of Florida neurologists are trying to ... Challenge grant from the National Institute of Neurological Disorders ...

(Date:12/15/2009)... environmental impacts, social dynamics, and production levels are ... of an agroecosystem. Positive or negative, these factors ... social groups to continuously adapt farming and food ... learning theory suggests that knowledge is gained as ... are especially valuable for environmental and agricultural educators ...

(Date:12/15/2009)... December 2009 - Scientists at VIB and Ghent University ... the treatment of septic shock, the major cause of ... of nitric oxide (NO) gas in mice with septic ... the animal,s organs showed much less damage, while their ... expectations, since it is generally assumed that nitric oxide ...

[0] UF to lead national effort to help patients with rare brain disease [0] Experiential learning teaches change and adaptation [0] Septic shock: Nitric oxide beneficial after all

... EPA,s ocean survey vessel, the OSV BOLD, will conduct a series ... in and around the San Juan Bay Estuary, Jobos Bay, La ... also be open to the public when it docks in San ... Feb. 23, the OSV BOLD will sail to the U.S. Virgin ...

... read stories about how to "grow your own organs" using ... this breakthrough has been elusive. A new report published in ... ( http://www.fasebj.org ) brings bioengineered organs a step closer, as ... describe how they were able to use a "scaffolding" material ...

... WASHINGTON, D.C. Neuroscientists at Georgetown University Medical Center ... looks like when someone anticipates an action or sensory ... issue of the Journal of Neuroscience , they ... of the brain responsible for preparing the body to ...

Other Biology News:EPA to study Puerto Rico waters and marine habitat 2 From stem cells to new organs: Stanford and NYU scientists cross threshold in regenerative medicine 2 Researchers capture wave of brain activity linked to anticipation 2

EPA to study Puerto Rico waters and marine habitat From stem cells to new organs: Stanford and NYU scientists cross threshold in regenerative medicine Researchers capture wave of brain activity linked to anticipation

Request Info...

... ,ICC and IHC Protocol Development ,Antibody ... Screenings in Animal or Human Cells ... Cells and Tissues ,Peroxidase, Alkaline Phosphatase, ... or Electron Microscopy ,Protein Localization in ...

Biology Products:

Morphine ELISA Kit, Single from Bio-Quant Inc.PCP ELISA Kit, Single from Bio-Quant Inc.Cotinine ELISA Kit, Single from Bio-Quant Inc.Immunodetection of Specific Proteins from QualTek Molecular Laboratories

Vanda Pharmaceuticals to Present at the Bank of America 2008 Healthcare ...( Presentation Will be Webcast Live...)